Actually then or around that time it had not been long before that it was $2.51 and hung around in the high $1s, and of course the real measure is market cap, not dollar amount and it is in a range of value in terms of market cap to not be suggested it should not be taken seriously. Clearly doctors around the world and regulators do take it seriously or they’d not be licensed to commercially manufacture in the UK and be allowed pre-marketing approval to deliver DCVax-L to local U.K. patients who can pay full price out of pocket.
That doesn’t happen with failed drugs or drug companies that are not thought well off. It would not have won the U.K. PIM designation or Hospital Exemption in Germany if it were so little regarded, regardless of whether those designations generated economic value.